Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Key Highlights
- ➤Cadrenal launches formal strategic process to maximize value across its portfolio
- ➤Tungsten Advisors appointed exclusive strategic financial advisor for the process
- ➤Potential transactions include asset sales, licensing, partnerships, and business combinations
- ➤FDA alignment establishes a Phase 3 development pathway for CAD-1005
- ➤Strategic process follows strong interest from potential strategic partners
Expert Statements
Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics
“Our pipeline has reached critical clinical and regulatory maturity, anchored by our recent alignment with the FDA on the Phase 3 development pathway for CAD-1005”
Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics
“Having received strong interest from potential strategic partners, we believe a formal strategic process provides the appropriate framework to evaluate opportunities across our portfolio and determine the paths that can maximize value for our shareholders while advancing these programs for patients.”
* Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 * Cadrenal has received strong interest from potential strategic partners * Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio.
The initiative builds on Cadrenal’s ongoing strategic partnering discussions and will evaluate a broad range of potential transactions involving the Company and its clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000, the Company’s second-generation 12-LOX platform. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.
Get started
Create a free account to read the full story.